secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001193125-24-254153
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Therapeutics prices $125M public offering of 7.8M shares at $16.00/share
--------------------------------------------------------------------------------

- Priced 7,812,500 shares at $16.00 per share; gross proceeds of $125.0M.
- Net proceeds expected ~$117.0M after underwriting discounts and expenses.
- Underwriters have 30-day option to purchase up to 1,171,875 additional shares.
- Closing expected November 12, 2024; Jefferies and Leerink Partners are joint book-runners.
- Proceeds for general corporate purposes including commercialization and R&D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000119312524254153/0001193125-24-254153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000119312524254153/d632981d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-254153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer